EHD3 and lung cancer: EHD3 hypermethylation was at least twofold higher in tumors than in matched normal tissues in only 15.2% (5/33) of patients with lung cancer, 40.0% (8/20) of those with breast cancer, and 13.3% (2/15) of those with uterine cancer (Figure S2).